A notable mention in this review represents an innovative class of medications that were initially developed for type 2 diabetes management, and also for resistant obesity treatment, two conditions which not only frequently coexist, but they also coexist with the subject of our review and these are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) (112). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.